HOME >> BIOLOGY >> NEWS
FDA approves VYTORIN, first and only to powerfully reduce LDL cholesterol through dual inhibition

WHITEHOUSE STATION and KENILWORTH, N.J., July 23, 2004 Merck/Schering-Plough Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved VYTORINTM (ezetimibe/simvastatin) for the treatment of high LDL cholesterol (LDL-C) in patients with primary hypercholesterolemia or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough. VYTORIN is the first and only product approved to treat the two sources of cholesterol by inhibiting the production of cholesterol in the liver and blocking the absorption of cholesterol in the intestine, including cholesterol from food. The active ingredients in VYTORIN are ezetimibe and simvastatin. The recommended starting dose of VYTORIN is 10/20 mg (10 mg ezetimibe/20 mg simvastatin).

"Many patients who continue to have high cholesterol despite diet and other lifestyle modifications may require powerful LDL cholesterol-lowering agents and to do this we frequently look to highly efficacious medicines to provide the reduction they need," said Christie Ballantyne, M.D., director of the Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, TX.

VYTORIN lowered LDL cholesterol by 52 percent at the recommended starting dose (10/20 mg) and 60 percent at the maximum dose (10/80 mg)

In a 12-week, multi-center, double-blind, placebo-controlled clinical study of 1,528 patients with LDL cholesterol levels of 145 mg/dL to 250 mg/dL, VYTORIN provided LDL cholesterol reductions of 52 percent at the recommended starting dose (10/20 mg), 55 percent at the 10/40 mg dose and 60 percent at the maximum dose (10/80 mg). VYTORIN is administered as a once-daily tablet and should be taken in the evening with or without food.

"VYTORIN is the first single cholesterol treatment to provide LDL cholesterol lowering through dual inhibition of cholesterol production and absorption. VYTORIN represents an important new treatment alte
'"/>


23-Jul-2004


Page: 1 2 3 4 5 6

Related biology news :

1. European Commission approves Herceptin + Taxotere as 1st-line therapy in HER2-positive breast cancer
2. FDA approves Raptiva (efalizumab) for chronic moderate-to-severe plaque psoriasis
3. FDA approves Abbotts Biaxin XL (clarithromycin extended-release tablet)for community-acquired pneumonia
4. FDA approves new treatment, Campath , humanized monoclonal antibody, for patients with B-cell chronic lymphocytic leukemia
5. DFG approves 14 new research training units
6. National Science Board approves five new NSF Science and Technology Centers
7. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
8. Newly identified master gene key in babys first breath
9. The book opens on the first tree genome
10. DuPont developing new protective suits for military, first responders
11. Joslin Diabetes Center adds first affiliate in California at Irvine Medical Center

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
Breaking Biology News(10 mins):
(Date:9/19/2017)... Pleasanton, Calif. and Washington, D.C. (PRWEB) , ... ... ... to delivering rapid care during an biological outbreak is about to be eliminated, ... When asked what makes ExcitePCR’s FireflyDX™ technologies different than other pathogen ...
(Date:9/19/2017)... ... September 19, 2017 , ... Band-LOK, LLC, an orthopedic ... that two new patents have been allowed by the USPTO on the proprietary ... “We continue to explore additional clinically-relevant designs for both the implants and the ...
(Date:9/17/2017)... , ... September 17, 2017 , ... ... the South Korean Ministry of Food and Drug Safety (KMFDS) for an Investigational ... against the Middle East Respiratory Syndrome coronavirus (MERS-CoV). The study in Korea represents ...
(Date:9/14/2017)... ... , ... Boston Strategic Partners, Inc. (BSP), a life-sciences and ... Research (HEOR) and ‘big data’ to provide in-depth analysis of pneumonia patients characteristics, ... trillion with nearly 1/3 spent on hospitalizations. BSP has access to real-world data ...
Breaking Biology Technology:
Cached News: